Evotec rises after second FDA IND acceptance in Bristol Myers Squibb partnership
BUZZ-Evotec rises after second FDA IND acceptance in Bristol Myers Squibb partnership ** Shares in Evotec EVTG.DE rise 3.7% in early Frankfurt trade after the drug discovery company said its protein degradation partnership with Bristol Myers Squibb BMY.N has received a second FDA Investigational New Drug acceptance
** Company says the second investigational candidate, a cereblon E3 ligase modulator, is expected to enter a Phase 1 clinical trial in 2027
** First candidate from the partnership entered Phase 1 testing in advanced clear cell renal cell carcinoma in March 2026
** Up to the previous session's close, shares were down 49.9% YTD
(Reporting by Basile Day)
Recent news on Bristol-Myers Squibb
See all newsEvotec rises after second FDA IND acceptance in Bristol Myers Squibb partnership
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows
Brief: Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease
Brief: Sichuan Biokin Pharmaceutical's Unit Receives Milestone Payment From Bristol-Myers Squibb